177 related articles for article (PubMed ID: 35550247)
21. Insulin Receptor Substrate 1, the Hub Linking Follicle-stimulating Hormone to Phosphatidylinositol 3-Kinase Activation.
Law NC; Hunzicker-Dunn ME
J Biol Chem; 2016 Feb; 291(9):4547-60. PubMed ID: 26702053
[TBL] [Abstract][Full Text] [Related]
22. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
23. Akt activation by Ca
Gocher AM; Azabdaftari G; Euscher LM; Dai S; Karacosta LG; Franke TF; Edelman AM
J Biol Chem; 2017 Aug; 292(34):14188-14204. PubMed ID: 28634229
[TBL] [Abstract][Full Text] [Related]
24. c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway.
Jin W; Yun C; Jeong J; Park Y; Lee HD; Kim SJ
J Biol Chem; 2008 Jan; 283(3):1391-1400. PubMed ID: 17991742
[TBL] [Abstract][Full Text] [Related]
25. PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells.
Hunzicker-Dunn ME; Lopez-Biladeau B; Law NC; Fiedler SE; Carr DW; Maizels ET
Proc Natl Acad Sci U S A; 2012 Oct; 109(44):E2979-88. PubMed ID: 23045700
[TBL] [Abstract][Full Text] [Related]
26. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT.
Zheng Y; Gierut J; Wang Z; Miao J; Asara JM; Tyner AL
Oncogene; 2013 Sep; 32(36):4304-12. PubMed ID: 23027128
[TBL] [Abstract][Full Text] [Related]
27. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract][Full Text] [Related]
28. nitric oxide triggers the phosphatidylinositol 3-kinase/Akt survival pathway in insulin-producing RINm5F cells by arousing Src to activate insulin receptor substrate-1.
Tejedo JR; Cahuana GM; Ramírez R; Esbert M; Jiménez J; Sobrino F; Bedoya FJ
Endocrinology; 2004 May; 145(5):2319-27. PubMed ID: 14764634
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract][Full Text] [Related]
30. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
31. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
32. FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.
Stanicka J; Rieger L; O'Shea S; Cox O; Coleman M; O'Flanagan C; Addario B; McCabe N; Kennedy R; O'Connor R
Oncogene; 2018 Jun; 37(23):3131-3150. PubMed ID: 29540831
[TBL] [Abstract][Full Text] [Related]
33. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.
Asano T; Yao Y; Shin S; McCubrey J; Abbruzzese JL; Reddy SA
Cancer Res; 2005 Oct; 65(20):9164-8. PubMed ID: 16230374
[TBL] [Abstract][Full Text] [Related]
34. Anticancer effects of α-mangostin in OVACAR-3 human ovarian carcinoma cells are mediated via involvement of reactive oxygen species, mitochondrial -mediated apoptosis, suppression of cell migration and invasion and m-TOR/PI3K/AKT signaling pathway.
Yu Y; Fei Z; Qin L
J BUON; 2020; 25(5):2293-2300. PubMed ID: 33277848
[TBL] [Abstract][Full Text] [Related]
35. Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation.
Hançer NJ; Qiu W; Cherella C; Li Y; Copps KD; White MF
J Biol Chem; 2014 May; 289(18):12467-84. PubMed ID: 24652289
[TBL] [Abstract][Full Text] [Related]
36. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.
Morrison KB; Tognon CE; Garnett MJ; Deal C; Sorensen PH
Oncogene; 2002 Aug; 21(37):5684-95. PubMed ID: 12173038
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
38. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
39. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Lu Y; Yu Q; Liu JH; Zhang J; Wang H; Koul D; McMurray JS; Fang X; Yung WK; Siminovitch KA; Mills GB
J Biol Chem; 2003 Oct; 278(41):40057-66. PubMed ID: 12869565
[TBL] [Abstract][Full Text] [Related]
40. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways.
Carvalho CR; Carvalheira JB; Lima MH; Zimmerman SF; Caperuto LC; Amanso A; Gasparetti AL; Meneghetti V; Zimmerman LF; Velloso LA; Saad MJ
Endocrinology; 2003 Feb; 144(2):638-47. PubMed ID: 12538627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
